Outsourcing Innovation eBook
Read the article:
Preparing for a New Wave of mRNA Technologies
Read the eBook:
Pharmaceutical Technology’s Outsourcing Innovation eBook
OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
The ability of the biopharma industry to meet the worldwide demand for messenger RNA vaccines was facilitated by contract development and manufacturing organizations. These partners promptly adapted their facilities and capabilities specifically for vaccine production, offering contract fill/finish and cold chain services required to meet demand. Examining the lessons learned from the COVID-19 pandemic, this article provides a perspective on the strategies and tactics taken to deliver a better drug development program and highlights the importance of remembering key lessons as the industry moves toward an era of new drug modalities.
Read this article in Pharmaceutical Technology’s February 2023 Outsourcing Innovation eBook.
Read the article:
Preparing for a New Wave of mRNA Technologies
Read the eBook:
Pharmaceutical Technology’s Outsourcing Innovation eBook
Jeong Jin-hyeok is a lead specialist in drug product at Samsung Biologics.
Pharmaceutical Technology
eBook: Outsourcing Innovation, February 2023
February 2023
Pages: 30–32
When referring to this article, please cite it as J. Jin-hyeok, “Preparing for a New Wave of mRNA Technologies," Pharmaceutical Technology Outsourcing Innovation eBook (February 2023).